122 related articles for article (PubMed ID: 30539842)
21. FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.
Zhang QY; Yue XQ; Jiang YP; Han T; Xin HL
Sci Rep; 2017 Mar; 7(1):396. PubMed ID: 28341836
[TBL] [Abstract][Full Text] [Related]
22. Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
Lee YC; Lee LM; Yang CH; Lin AM; Huang YC; Hsu CC; Chen MS; Chi CW; Yin PH; Kuo CD; Liao JF; Lee HC
Oncol Rep; 2013 Jan; 29(1):237-43. PubMed ID: 23128522
[TBL] [Abstract][Full Text] [Related]
23. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.
Zhang L; Ji Q; Liu X; Chen X; Chen Z; Qiu Y; Sun J; Cai J; Zhu H; Li Q
Cancer Sci; 2013 May; 104(5):604-10. PubMed ID: 23363445
[TBL] [Abstract][Full Text] [Related]
24. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
25. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met/Akt/mTOR pathway in human osteosarcoma cells.
Mei L; Sang W; Cui K; Zhang Y; Chen F; Li X
Cancer Sci; 2019 Feb; 110(2):582-595. PubMed ID: 30520540
[TBL] [Abstract][Full Text] [Related]
26. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells.
Chen YN; Chen JC; Yin SC; Wang GS; Tsauer W; Hsu SF; Hsu SL
Int J Cancer; 2002 Jul; 100(2):158-65. PubMed ID: 12115564
[TBL] [Abstract][Full Text] [Related]
27. [Effects of interventional therapy with norcantharidin microsphere on hepatoma in rats and its mechanism].
Li Q; Fan ZZ; Li XQ; Liu XH; Sun J; Gu W; Heng P; Gao H
Zhong Xi Yi Jie He Xue Bao; 2006 Jul; 4(4):378-83. PubMed ID: 16834975
[TBL] [Abstract][Full Text] [Related]
28. Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro.
Fan YZ; Fu JY; Zhao ZM; Chen CQ
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):72-80. PubMed ID: 17287171
[TBL] [Abstract][Full Text] [Related]
29. Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization.
Lu S; Gao Y; Huang X; Wang X
Int J Biol Sci; 2014; 10(4):415-25. PubMed ID: 24719559
[TBL] [Abstract][Full Text] [Related]
30. Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction.
Yeh CH; Yang YY; Huang YF; Chow KC; Chen MF
Chin J Integr Med; 2012 Sep; 18(9):676-82. PubMed ID: 22936321
[TBL] [Abstract][Full Text] [Related]
31. Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma.
Yang H; Guo W; Xu B; Li M; Cui J
Anticancer Drugs; 2007 Nov; 18(10):1133-7. PubMed ID: 17893513
[TBL] [Abstract][Full Text] [Related]
32. Norcantharidin induce apoptosis in human nasopharyngeal carcinoma through caspase and mitochondrial pathway.
Chen AW; Tseng YS; Lin CC; Hsi YT; Lo YS; Chuang YC; Lin SH; Yu CY; Hsieh MJ; Chen MK
Environ Toxicol; 2018 Mar; 33(3):343-350. PubMed ID: 29193574
[TBL] [Abstract][Full Text] [Related]
33. Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer.
Li XY; Guan QX; Shang YZ; Wang YH; Lv SW; Yang ZX; Wang R; Feng YF; Li WN; Li YJ
World J Gastroenterol; 2021 Jul; 27(26):4208-4220. PubMed ID: 34326620
[TBL] [Abstract][Full Text] [Related]
34. Regulation of demethylation and re-expression of RASSF1A gene in hepatocellular carcinoma cell lines treated with NCTD in vitro.
Wang Y; Xu M; Di ZH; Zhang J; Mao XQ; Sun HB
J Cancer Res Ther; 2015; 11(4):818-22. PubMed ID: 26881524
[TBL] [Abstract][Full Text] [Related]
35. [Molecular mechanism of norcantharidin inducing apoptosis in liver cancer cells].
Li GQ; Zhang SJ; Lü JF; Wu Y; Li J; Zhang G; Yu JT
Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(30):2145-8. PubMed ID: 21029633
[TBL] [Abstract][Full Text] [Related]
36. Glycyrrhetinic Acid-Modified Norcantharidin Nanoparticles for Active Targeted Therapy of Hepatocellular Carcinoma.
Zhang H; Jiang Y; Ni X; Chen L; Wu M; Liu J; Yang B; Shan X; Yang L; Fan J; Chen Y; Wu J; Fu S
J Biomed Nanotechnol; 2018 Jan; 14(1):114-126. PubMed ID: 29463369
[TBL] [Abstract][Full Text] [Related]
37. Genistein reinforces the inhibitory effect of Cisplatin on liver cancer recurrence and metastasis after curative hepatectomy.
Chen P; Hu MD; Deng XF; Li B
Asian Pac J Cancer Prev; 2013; 14(2):759-64. PubMed ID: 23621233
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin plus norcantharidin alter the expression of TGF-β1/Smads signaling pathway in hepatocellular carcinoma.
Li KY; Shi CX; Huang JZ; Tang KL
Bratisl Lek Listy; 2017; 118(2):85-88. PubMed ID: 28814088
[TBL] [Abstract][Full Text] [Related]
39. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
[TBL] [Abstract][Full Text] [Related]
40. A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice.
Liu XJ; Zheng YB; Li Y; Wu SY; Zhen YS
PLoS One; 2014; 9(12):e115790. PubMed ID: 25531414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
